We utilized two immunotherapy-related datasets: the uroepithelial carcinoma dataset (IMvigor210), comprising samples treated with anti-PD-1, and the malignant melanoma dataset (GSE91016), involving samples treated with both anti-PD-1 and anti-CTLA-4. This evidence concerns the gene CTLA4 and melanoma.